TEVA vs GSK
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TEVA · Teva Pharmaceutical Industries$39.23 ▲ 1.79%
GSK · GlaxoSmithKline$47.76 ▼ 0.13%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TEVA +58.4%
- GSK +4.3%
Head to head
| Metric | TEVA | GSK |
|---|---|---|
| Price | $39.23 | $47.76 |
| Change today | ▲ 1.79% | ▼ 0.13% |
| Market cap | $45.77B | $95.73B |
| Return, 3 months | +6.2% | -7.8% |
| Return, year to date | +25.7% | -0.1% |
| Return, 1 year | +62.0% | +3.9% |
| P/E (TTM) | 91.2 | 17.1 |
| P/B | 5.7 | 3.9 |
| P/E percentile vs own 5y | 99th | 77th |
| Dividend yield | – | 3.75% |
| Revenue growth (YoY, latest qtr) | -1.9% | +4.0% |
| Net profit growth (YoY) | -46.1% | -20.6% |
| Gross margin | 53.5% | 72.6% |
| Operating margin | 19.2% | 19.1% |
| Net margin | 2.9% | 13.0% |
| Return on equity | 6.6% | 24.9% |
| Analyst target vs. price | +31.4% | +17.0% |
| Analyst buy share | 100% | 0% |
| RSI (14) | 40 | 39 |
| 30-day volatility | 38.6% | 29.9% |
| Max drawdown, 1 year | -21.8% | -22.4% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GSK is the largest of the group by market value.
- TEVA has returned the most over the past year.
- GSK carries the lowest trailing P/E.
- GSK is growing revenue fastest.
- GSK keeps the most profit per dollar of sales.
- GSK has been the calmest stock over the last 30 days.